Method for treating a Human patient with Multiple Sclerosis with laquinimod, at a daily dose of about 1,2mg； a AForm of 1.2 mg oral dosage unit and a Carrier laquinimod
Disclosed herein are methods of treating a human patient afflicted with multiple sclerosis (MS) or presenting a clinically isolated syndrome (CIS), for treating a human subject by providing neuroprotection, and of treating a human patient afflicted with MS or presenting a CIS by increasing the time to confirmed disease progression and/or confirmed relapse or reducing brain atrophy, comprising orally administering a daily dose of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof. Also disclosed is a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in treating a human patient afflicted with MS or presenting a CIS, in treating a human subject by providing neuroprotection, or in treating a human patient afflicted with MS or presenting a CIS by increasing the time to confirmed disease progression and/or confirmed relapse or reducing brain atrophy.USO DE LAQUINIMOD O UNA SAL FARMACÉUTICAMENTE ACEPTABLE PARA TRATAR LA ESCLEROSIS MÚLTIPLE Y PARA PROPORCIONAR NEUROPROTECCIÓN FORMULADO PARA ADMINISTRACIÓN ORAL EN UNA DOSIS DIARIA DE ALREDEDOR DE 1,2 MG LAQUINIMOD； Y USO DE UNA FORMA DE DOSIFICACIÓN UNITARIA ORAL QUE COMPRENDE ALREDEDOR DE 1,2 MG DE LAQUINIMOD O UNA SAL DE LA MISMA.
